Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Share-based Compensation (2021 - 2025)

Rani Therapeutics Holdings (RANI) has 5 years of Share-based Compensation data on record, last reported at $2.3 million in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 42.02% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $13.6 million, down 18.0%, while the annual FY2024 figure was $16.0 million, 15.66% down from the prior year.
  • Share-based Compensation reached $2.3 million in Q3 2025 per RANI's latest filing, down from $3.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $18.7 million in Q3 2021 and bottomed at $283000.0 in Q2 2021.
  • Average Share-based Compensation over 5 years is $4.4 million, with a median of $4.0 million recorded in 2024.
  • The widest YoY moves for Share-based Compensation: up 1304.95% in 2022, down 76.45% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $3.2 million in 2021, then soared by 42.19% to $4.5 million in 2022, then fell by 0.29% to $4.5 million in 2023, then fell by 11.03% to $4.0 million in 2024, then tumbled by 41.29% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.3 million in Q3 2025, $3.3 million in Q2 2025, and $3.9 million in Q1 2025.